China approves Lilly's orforglipron, its first oral GLP-1 weight-management pill there

Lilly has reportedly received Chinese regulatory approval for orforglipron, which would make it the first company to sell a GLP-1 weight-management pill in China. Coverage frames the approval as an early opening in a Chinese obesity-drug market that is gaining momentum and is estimated at about $4.5 billion. The report says the pill would compete with Lilly's own weekly injectable, as well as products from Novo Nordisk, Pfizer and Innovent. This was based on a single press report and was not confirmed in a primary regulatory release.

1. Reported Chinese approval of orforglipron, Lilly's oral GLP-1 candidate for weight management.
2. Coverage describes Lilly as the first company to offer a GLP-1 weight-management pill in China.
3. Chinese obesity-drug market was described as roughly $4.5 billion in potential size.
4. The pill would compete with Lilly's own once-weekly injection and products from Novo Nordisk, Pfizer and Innovent Biologics.
5. Foundayo is the U.S. brand name for orforglipron, approved by the FDA for adults with obesity earlier in 2026, per Lilly's Q1 2026 results release.